Canada - English - Health Canada

homeocan inc. - phytolacca decandra - globules - 2x - phytolacca decandra 2x - homeopathic products

Canada - English - Health Canada

dolisos canada inc. - phytolacca decandra - globules - 2x - phytolacca decandra 2x - homeopathic products

United States - English - NLM (National Library of Medicine)

healing natural oils - phytolacca americana root (unii: 11e6vi8veg) (phytolacca americana root - unii:11e6vi8veg), thuja occidentalis leafy twig (unii: 1nt28v9397) (thuja occidentalis leafy twig - unii:1nt28v9397) - phytolacca americana root 12 [hp_c] in 11 ml - phytolacca decandra -12c hpus  (for warts), thuja occidentalis -12c hpus (locally for warts) the letters ‘hpus’ indicate that the components in this product are officially monographed in the homoeopathic pharmacopoeia of the united states for the treatment of wart symptoms associated with common warts (cauliflower like appearance), plantar warts (under the feet) and flat warts.

United States - English - NLM (National Library of Medicine)

sciegen pharmaceuticals inc - phytonadione (unii: a034se7857) (phytonadione - unii:a034se7857) - phytonadione is indicated for the treatment of adults with the following coagulation disorders which are due to faulty formation of factors ii, vii, ix and x when caused by vitamin k deficiency or interference with vitamin k activity. • anticoagulant-induced hypoprothrombinemia caused by coumarin or indanedione derivatives; • hypoprothrombinemia secondary to antibacterial therapy; • hypoprothrombinemia secondary to factors limiting absorpsion or synthesis of vitamin k, e.g., obstructive jaundice, biliary fistula, sprue, ulcerative colitis, celiac disease, intestinal resection, cystic fibrosis of the pancrease, and regional enteritis; • other drug-induced hypoprothrombinemia where it is definitely shown that the result is due to interference with vitamin k metabolism, e.g., salicylates. phytonadione is contraindicated in patients with a history of a hypersensitivity reaction to phytonadione or inactive ingredients [see description (11)] . risk summary published studies with

United States - English - NLM (National Library of Medicine)

avkare - phytonadione (unii: a034se7857) (phytonadione - unii:a034se7857) - phytonadione tablets are indicated for the treatment of adults with the following coagulation disorders which are due to faulty formation of factors ii, vii, ix and x when caused by vitamin k deficiency or interference with vitamin k activity. - anticoagulant-induced hypoprothrombinemia caused by coumarin or indanedione derivatives. - hypoprothrombinemia secondary to antibacterial therapy. - hypoprothrombinemia secondary to factors limiting absorpsion or synthesis of vitamin k, e.g., obstructive jaundice, biliary fistula, sprue, ulcerative colitis, celiac disease, intestinal resection, cystic fibrosis of the pancrease, and regional enteritis. - other drug-induced hypoprothrombinemia where it is definitely shown that the result is due to interference with vitamin k metabolism, e.g., salicylates. phytonadione tablets are contraindicated in patients with a history of a hypersensitivity reaction to phytonadione or inactive ingredients [see description ( 11) ] . risk summary published studies with t

United States - English - NLM (National Library of Medicine)

agnitio inc. - phytonadione (unii: a034se7857) (phytonadione - unii:a034se7857) - phytonadione tablets are indicated for the treatment of adults with the following coagulation disorders which are due to faulty formation of factors ii, vii, ix and x when caused by vitamin k deficiency or interference with vitamin k activity. - anticoagulant-induced hypoprothrombinemia caused by coumarin or indanedione derivatives. - hypoprothrombinemia secondary to antibacterial therapy. - hypoprothrombinemia secondary to factors limiting absorpsion or synthesis of vitamin k, e.g., obstructive jaundice, biliary fistula, sprue, ulcerative colitis, celiac disease, intestinal resection, cystic fibrosis of the pancrease, and regional enteritis. - other drug-induced hypoprothrombinemia where it is definitely shown that the result is due to interference with vitamin k metabolism, e.g., salicylates.          phytonadione tablets are contraindicated in patients with a history of a hypersensitivity reaction to phytonadione or inactive ingredients [see description (11)] . risk summary published studies with the use o

United States - English - NLM (National Library of Medicine)

exelan pharmaceuticals, inc. - phytonadione (unii: a034se7857) (phytonadione - unii:a034se7857) - phytonadione is indicated for the treatment of adults with the following coagulation disorders which are due to faulty formation of factors ii, vii, ix and x when caused by vitamin k deficiency or interference with vitamin k activity. phytonadione is indicated for the treatment of adults with the following coagulation disorders which are due to faulty formation of factors ii, vii, ix and x when caused by vitamin k deficiency or interference with vitamin k activity. • anticoagulant-induced hypoprothrombinemia caused by coumarin or indanedione derivatives; • hypoprothrombinemia secondary to antibacterial therapy; • hypoprothrombinemia secondary to factors limiting absorpsion or synthesis of vitamin k, e.g., obstructive jaundice, biliary fistula, sprue, ulcerative colitis, celiac disease, intestinal resection, cystic fibrosis of the pancrease, and regional enteritis; • other drug-induced hypoprothrombinemia where it is definitely shown that the result is due to interference with vitamin k metabolism, e.g., salicylates. phytonadione is contraindicated in patients with a history of a hypersensitivity reaction to phytonadione or inactive ingredients [see description (11)]. risk summary published studies with the use of phytonadione during pregnancy have not reported a clear association with phytonadione and adverse developmental outcomes [see data] . there are maternal and fetal risks associated with vitamin k deficiency during pregnancy [see clinical considerations] . animal reproduction studies have not been conducted with phytonadione. the estimated background risk for the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. clinical considerations disease-associated maternal and/or embryo/fetal risk pregnant women with vitamin k deficiency hypoprothrombinemia may be at increased risk for bleeding diatheses during pregnancy and hemorrhagic events at delivery. subclinical vitamin k deficiency during pregnancy has been implicated in rare cases of fetal intracranial hemorrhage. data human data phytonadione has been measured in cord blood of infants whose mothers were treated with phytonadione during pregnancy in concentrations lower than seen in maternal plasma. administration of vitamin k 1to pregnant women shortly before delivery increased both maternal and cord blood concentrations. published data do not report a clear association with phytonadione and adverse maternal or fetal outcomes when used during pregnancy. however, these studies cannot definitively establish the absence of any risk because of methodologic limitations including small sample size and lack of blinding. animal data in pregnant rats receiving vitamin k 1orally, fetal plasma and liver concentrations increased following administration, supporting placental transfer. risk summary phytonadione is present in breastmilk. there are no data on the effects of phytonadione on the breastfed child or on milk production. the developmental and health benefits of breastfeeding should be considered along with the clinical need for phytonadione and any potential adverse effects on the breastfed child from phytonadione or from the underlying maternal condition. safety and effectiveness in pediatric patients have not been established with phytonadione. hemolysis, jaundice, and hyperbilirubinemia in newborns, particularly in premature infants, have been reported with vitamin k. clinical studies of phytonadione did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. other reported clinical experience has not identified differences in responses between the elderly and younger patients. in general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

United States - English - NLM (National Library of Medicine)

cipla usa., inc. - phytonadione (unii: a034se7857) (phytonadione - unii:a034se7857) - phytonadione is indicated for the treatment of adults with the following coagulation disorders which are due to faulty formation of factors ii, vii, ix and x when caused by vitamin k deficiency or interference with vitamin k activity. - anticoagulant-induced hypoprothrombinemia caused by coumarin or indanedione derivatives; - hypoprothrombinemia secondary to antibacterial therapy; - hypoprothrombinemia secondary to factors limiting absorpsion or synthesis of vitamin k, e.g., obstructive jaundice, biliary fistula, sprue, ulcerative colitis, celiac disease, intestinal resection, cystic fibrosis of the pancrease, and regional enteritis; - other drug-induced hypoprothrombinemia where it is definitely shown that the result is due to interference with vitamin k metabolism, e.g., salicylates. phytonadione is contraindicated in patients with a history of a hypersensitivity reaction to phytonadione or inactive ingredients [see description (11)]. published studies with the use of phytonadione during pregnancy have not reported a clear association with phytonadione and adverse developmental outcomes [see data] . there are maternal and fetal risks associated with vitamin k deficiency during pregnancy [see clinical considerations] . animal reproduction studies have not been conducted with phytonadione. the estimated background risk for the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. clinical considerations disease-associated maternal and/or embryo/fetal risk pregnant women with vitamin k deficiency hypoprothrombinemia may be at increased risk for bleeding diatheses during pregnancy and hemorrhagic events at delivery. subclinical vitamin k deficiency during pregnancy has been implicated in rare cases of fetal intracranial hemorrhage. data human data phytonadione has been measured in cord blood of infants whose mothers were treated with phytonadione during pregnancy in concentrations lower than seen in maternal plasma. administration of vitamin k1 to pregnant women shortly before delivery increased both maternal and cord blood concentrations. published data do not report a clear association with phytonadione and adverse maternal or fetal outcomes when used during pregnancy. however, these studies cannot definitively establish the absence of any risk because of methodologic limitations including small sample size and lack of blinding. animal data in pregnant rats receiving vitamin k1 orally, fetal plasma and liver concentrations increased following administration, supporting placental transfer. risk summary phytonadione is present in breastmilk. there are no data on the effects of phytonadione on the breastfed child or on milk production. the developmental and health benefits of breastfeeding should be considered along with the clinical need for phytonadione and any potential adverse effects on the breastfed child from phytonadione or from the underlying maternal condition. safety and effectiveness in pediatric patients have not been established with phytonadione. hemolysis, jaundice, and hyperbilirubinemia in newborns, particularly in premature infants, have been reported with vitamin k. clinical studies of phytonadione did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. other reported clinical experience has not identified differences in responses between the elderly and younger patients. in general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

United States - English - NLM (National Library of Medicine)

jubilant hollisterstier llc - epidermophyton floccosum (unii: 6jr6jtn25s) (epidermophyton floccosum - unii:6jr6jtn25s) - epidermophyton floccosum 0.1 g in 1 ml - allergenic extracts are indicated for use in diagnosis and immunotherapy of patients presenting symptoms of allergy (hay fever, rhinitis, etc.) to specific environmental allergens. the selection of allergenic extracts to be used should be based on a thorough and carefully taken history of hypersensitivity, and confirmed by skin testing. the use of mixed or unrelated antigens for skin testing is not recommended since, in the case of a positive reaction, it does not indicate which component of the mix is responsible for the reaction, while, in the case of a negative reaction, it fails to indicate whether the individual antigens at full concentration would give a positive reaction. utilization of such mixes for compounding a treatment may result, in the former case, in administering unnecessary antigens and, in the latter case, in the omission of a needed antigen. avoidance of allergens is to be advocated if possible, but cannot always be attained, e.g., allergy to dog dander in kennel owners and employees,

United States - English - NLM (National Library of Medicine)

peaceful mountain, inc. - phytolacca americana root (unii: 11e6vi8veg) (phytolacca americana root - unii:11e6vi8veg), bellis perennis (unii: 2hu33i03uy) (bellis perennis - unii:2hu33i03uy), ledum palustre twig (unii: 877l01iz0p) (ledum palustre twig - unii:877l01iz0p), ruta graveolens flowering top (unii: n94c2u587s) (ruta graveolens flowering top - unii:n94c2u587s), comfrey root (unii: m9vvz08ekq) (comfrey root - unii:m9vvz08ekq), whey (unii: 8617z5fmf6) (whey - unii:8617z5fmf6), magnesium phosphate, dibasic trihydrate (unii: - phytolacca americana root 1 [hp_x] in 1 g - may temporarily relieve minor aches and pains of muscles and joints.** **these statements are based upon traditional homeopathic principles. they have not been reviewed by the food and drug administration. may temporarily relieve minor aches and pains of muscles and joints.** **these statements are based upon traditional homeopathic principles. they have not been reviewed by the food and drug administration.